Efficacy of Intramammary Extended Therapy Using Ceftiofur (Spectramast® LC) against Clinical Mastitis of Holstein Cows

Authors

  • G. Truchetti Departement des sciences cliniques, Faculte de medecine veterinaire, St-Hyacinthe, Quebec J2S 2M2
  • J. P. Roy Departement des sciences cliniques, Faculte de medecine veterinaire, St-Hyacinthe, Quebec J2S 2M2
  • L. DesCôteaux Departement des sciences cliniques, Faculte de medecine veterinaire, St-Hyacinthe, Quebec J2S 2M2
  • E. Bouchard Departement des sciences cliniques, Faculte de medecine veterinaire, St-Hyacinthe, Quebec J2S 2M2
  • M. Doucet Departement de biomedecine veterinaire, Faculte de medecine veterinaire, St-Hyacinthe, Quebec J2S 2M2
  • D. Scholl Departement de pathologie et microbiologie, Faculte de medecine veterinaire, St-Hyacinthe, Quebec J2S 2M2

DOI:

https://doi.org/10.21423/aabppro20104117

Keywords:

clinical mastitis, Ceftiofur, extended therapy, Staphylococcus aureus, streptococci

Abstract

Little research has focused on extended therapy for cows with clinical mastitis during lactation. Ceftiofur should be effective against a wide range of mastitis pathogens including gram-positive and gram-negative bacteria. It could be considered as a reasonable choice for treatment of clinical mastitis. The objective of the present study was to determine if extended therapy would increase cure rates of a ceftiofur treatment for non-acute clinical mastitis, for all bacteria and more specifically for Staphylococcus aureus and streptococci. The hypothesis was that extended therapy would enhance the cure rate of ceftiofur for non-acute clinical mastitis.

Cover image of the 43rd Conference Proceedings: Two short-horned cattle grazing in a field, surrounded by a flock of egrets. Yellow background.

Downloads

Published

2010-08-19

Issue

2010

Section

Research Summaries 1

Most read articles by the same author(s)

1 2 3 > >>